Answers are grounded in this paper and cite their sources.
Ziel/Aim: Our goal was to investigate if the total tumor burden (TTB) can improve the prognostic value of PET in aggressive lymphoma. Methodik/Methods: PET data from the PETAL Trial [ 1 ] were re-evaluated. Image data as well as maximum baseline SUV and maximum interim SUV (after 2 cycles of R-CHOP) were provided by the PETAL-Trial coordinators. So far, 234 patients could be included. In the corresponding baseline PET all affected lesions were delineated with a previously trained neural network. All delineations were visually confirmed or corrected by an experienced nuclear medicine specialist, if necessary. From the resulting VOIs TTB was derived. Survival analyses with respect to overall survival (OS) and event free survival (EFS) were performed for baseline SUVmax, Δ SUVmax (> -66%), and TTB. Ergebnisse/Results: Survival analyses revealed Δ SUVmax and TTB as prognostic factors for both OS (P<0001 and P<0.025, respectively) and EFS (p<0.001 and p<0.001, respectively). Baseline SUVmax did not show a significant effect for neither. In multivariate analysis, Δ SUVmax (p<0.001) and TTB (p=0.037) remained significant for both endpoints indicating their independent prognostic value. Schlussfolgerungen/Conclusion: Our results show that TTB adds independent prognostic information to Δ SUVmax, which increases the overall prognostic value of PET in this cohort. Further investigations are necessary to confirm these preliminary results. Publication History Article published online: 12 March 2025 © 2025. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
No takes yet. Share an insight, caveat, or question.
Hoberück et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: